Catalent announced a nearly $100 million investment to expand Catalent Biologics Madison over the next three years. The company develops and manufactures pharmaceutical products made from living cells instead of chemicals at the Madison facility. Catalent announced a similar investment this week at its facility in Bloomington, Indiana. It will be the second expansion of operations at Catalent Biologics Madison in about two years.